October 25, 2016 5:54 AM ET


Company Overview of Kindred Biosciences, Inc.

Company Overview

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates include Zimeta, a pyrazolone anti-inflammatory drug, for the treatment of fever in horses; and KIND-010 for management of weight loss in cats and feline epo for anemia in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcer syndrome; and KIND-015 for the treatment of metabolic syndrome in horses. It is also developing biologics products, such as KIND-510...

1555 Bayshore Highway

Suite 200

Burlingame, CA 94010

United States

Founded in 2012

39 Employees



Key Executives for Kindred Biosciences, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $500.0K
Co-Founder, Chief Operating Officer and Secretary
Age: 49
Total Annual Compensation: $422.5K
Chief Scientific Officer and Executive Vice President of Regulatory Affairs & Quality
Age: 65
Total Annual Compensation: $356.5K
Compensation as of Fiscal Year 2015.

Kindred Biosciences, Inc. Key Developments

Kindred Biosciences, Inc. Receives Approval of Effectiveness Technical Section from FDA for Zimeta New Animal Drug Application

Kindred Biosciences, Inc. announced it has received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration's Center for Veterinary Medicine for Zimeta™ (dipyrone injection) approving the technical section. The basis for this complete letter was a multicenter, randomized, blinded, placebo-controlled pivotal study that enrolled 138 horses to assess the effectiveness of Zimeta. The primary endpoint was improvement (a 2°F or greater decrease in temperature from baseline) or resolution of fever (a return to normothermia (=101.0°F)) at hour 6 following treatment. One hundred and thirty-seven horses (103 Zimeta and 34 control product) were included in the statistical analysis for effectiveness. At 6 hours post-treatment, the success rate was 74.8% (77/103) of Zimeta-treated horses and 20.6% (7/34) of control horses. The results of the field study demonstrate that Zimeta administered at 30 mg/kg intravenously was effective for the control of pyrexia 6 hours following treatment administration. KindredBio has responded to the first round of review by the FDA for the CMC technical section. KindredBio is in the process of responding to the first round of review by the FDA on the safety technical section. KindredBio expects the approval of Zimeta in the first half of 2017 if the FDA review process is rapid.

Kindred Biosciences, Inc. Submits Final Major New Animal Drug Application Technical Section for Safety for Mirataz to FDA

Kindred Biosciences, Inc. has announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Mirataz™ (mirtazapine 2% transdermal ointment, KIND-010). This is the final major technical section to be submitted for Mirataz. The Chemistry, Manufacturing, and Controls technical section was submitted in May 2016 and the Effectiveness technical section was submitted in August 2016. In the target animal safety study, Mirataz was generally well-tolerated and no significant safety concerns were identified at 1X, 3X, or 5X the proposed label dose (2 mg/cat applied once daily to the inner pinna of the ear) for 42 consecutive days of transdermal application. At the proposed label dose, topical administration of mirtazapine ointment was associated with mild, reversible skin changes at the site of dose application (ear).

Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from S&P Global BMI Index

Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from S&P Global BMI Index

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kindred Biosciences, Inc., please visit www.kindredbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.